Neoleukin Therapeutics (NLTX) Competitors $22.54 +1.07 (+4.98%) As of 07/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. PHAR, NUVB, AVBP, ANAB, TRVI, IMTX, MRVI, DAWN, DNA, and STOKShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Pharming Group (PHAR), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), AnaptysBio (ANAB), Trevi Therapeutics (TRVI), Immatics (IMTX), Maravai LifeSciences (MRVI), Day One Biopharmaceuticals (DAWN), Ginkgo Bioworks (DNA), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors Pharming Group Nuvation Bio ArriVent BioPharma AnaptysBio Trevi Therapeutics Immatics Maravai LifeSciences Day One Biopharmaceuticals Ginkgo Bioworks Stoke Therapeutics Neoleukin Therapeutics (NASDAQ:NLTX) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Do institutionals & insiders hold more shares of NLTX or PHAR? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend NLTX or PHAR? Pharming Group has a consensus target price of $30.00, indicating a potential upside of 184.06%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NLTX or PHAR more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -4.14%. Pharming Group's return on equity of -6.01% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Pharming Group -4.14%-6.01%-3.23% Which has more volatility and risk, NLTX or PHAR? Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Does the media prefer NLTX or PHAR? In the previous week, Pharming Group had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Pharming Group and 0 mentions for Neoleukin Therapeutics. Pharming Group's average media sentiment score of 0.62 beat Neoleukin Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Pharming Group Positive Which has higher valuation & earnings, NLTX or PHAR? Pharming Group has higher revenue and earnings than Neoleukin Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.25Pharming Group$320.71M2.26-$11.84M-$0.20-52.81 SummaryPharming Group beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.83M$760.92M$5.50B$9.40BDividend YieldN/A4.84%4.25%4.09%P/E Ratio-7.251.4028.1319.86Price / SalesN/A25.51424.9198.68Price / CashN/A19.5635.5357.53Price / Book2.036.728.235.71Net Income-$57.56M-$4.32M$3.24B$257.80M7 Day Performance6.02%1.14%0.66%1.12%1 Month Performance18.82%2.55%8.07%11.30%1 Year Performance-49.17%-1.89%28.44%16.88% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$22.54+5.0%N/A-53.1%$211.83MN/A-7.2590PHARPharming Group2.0618 of 5 stars$10.50+6.2%$30.00+185.8%+16.6%$714.04M$297.20M-52.48280News CoverageGap DownNUVBNuvation Bio3.1432 of 5 stars$2.07-0.7%$7.17+247.1%-34.9%$709.78M$7.87M-0.8960AVBPArriVent BioPharma2.4543 of 5 stars$20.52+1.7%$40.00+94.9%+10.5%$701.99MN/A-5.4440ANABAnaptysBio1.6677 of 5 stars$23.65+0.9%$42.38+79.2%-22.1%$694.90M$91.28M-4.88100TRVITrevi Therapeutics3.8778 of 5 stars$5.86-1.6%$20.88+256.4%+131.4%$686.97MN/A-13.0220IMTXImmatics3.1048 of 5 stars$5.70+2.8%$14.67+157.5%-51.2%$686.15M$168.65M-33.20260News CoverageMRVIMaravai LifeSciences3.5135 of 5 stars$2.68+3.1%$6.64+147.7%-72.6%$682.49M$259.18M-2.35610Positive NewsDAWNDay One Biopharmaceuticals2.5763 of 5 stars$6.73+1.5%$29.00+330.8%-58.7%$682.25M$131.16M-9.4860DNAGinkgo Bioworks0.7732 of 5 stars$11.04-2.8%$5.77-47.7%N/A$650.91M$227.04M-1.21640News CoverageSTOKStoke Therapeutics4.1504 of 5 stars$11.87+1.5%$23.20+95.5%-19.3%$650.29M$36.56M15.08100 Related Companies and Tools Related Companies Pharming Group Alternatives Nuvation Bio Alternatives ArriVent BioPharma Alternatives AnaptysBio Alternatives Trevi Therapeutics Alternatives Immatics Alternatives Maravai LifeSciences Alternatives Day One Biopharmaceuticals Alternatives Ginkgo Bioworks Alternatives Stoke Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLTX Stock Alerts